Nanoscope Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare has granted both Sakigake (fast-track) and Orphan Drug designations to its lead optogenetic therapy MCO-010 for treating severe inherited retinal diseases, marking the first time a retinal gene therapy has received these combined designations in Japan. The regulatory milestones are expected to accelerate development and global commercialization efforts alongside ongoing FDA and EMA designations.
